Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04703686
Title Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Lymphoma Academic Research Organisation
Indications

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma

mantle cell lymphoma

non-Hodgkin lymphoma

Therapies

Obinutuzumab + RO7082859

Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.